MAP2K7 and neoplasm: Donafenib is an orally administered small molecule multikinase inhibitor that exhibits anti-tumor properties and has multiple targets; it can inhibit not only the activity of multiple tyrosine kinases, including vascular endothelial growth factor receptor and platelet-derived growth factor receptor, but also various Raf kinases and the downstream Raf/MEK/ERK signal transduction pathway, thereby suppressing tumor cell proliferation and angiogenesis (6).